Acadia Pharmaceuticals (ACAD) FY2018 results: revenue $224 million, up 79.2% on the year
Acadia Pharmaceuticals Inc. (ACAD) reported revenue of $224 million for fiscal 2018, the year ended 31 December 2018, up 79.2% on the year before. Net income was -$245 million, and diluted earnings per share $-1.94. The figures are the company's own, from the 10-K it filed with the SEC on 27 February 2019.
Revenue
$224 million
+79.2% on the year
FY2011FY2018
Operating margin
-110.6%
-234.1% a year earlier
FY2011FY2018
Net income
-$245 million
FY2011FY2018
Diluted EPS
-$1.94
FY2011FY2018
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2018
FY2017
FY2016
On the year
Last 8 years
Revenue
224
125
17.3
+79.2%
Cost of revenue
12.4
9.1
3.1
+36.4%
Gross profit
211
116
14.3
+82.5%
Gross margin
94.5%
92.7%
82.2%
Research and development
187
149
99.3
+25.5%
Selling, general and administrative
266
255
186
+4.2%
Operating income
-247
-292
-273
Operating margin
-110.6%
-234.1%
-1574.1%
Pre-tax income
-244
-288
-270
Income tax
1.3
1.1
1.3
+12.2%
Net income
-245
-289
-271
Net margin
-109.6%
-231.7%
-1565.9%
Diluted EPS
-$1.94
-$2.36
-$2.34
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2018
FY2017
FY2016
On the year
Last 8 years
Operating cash flow
-167
-218
-208
Capital expenditure
2.1
0.8
1.5
+159.1%
Free cash flow
-170
-219
-210
Free cash flow margin
-75.8%
-175.0%
-1211.2%
Cash from investing
-71.5
92.5
-262
Cash from financing
307
31.2
534
+883.2%
Depreciation and amortisation
3.0
2.7
1.8
+10.8%
Share-based compensation
81.6
75.5
55.3
+8.0%
Shares outstanding at period end
144m
124m
121m
+15.6%
Balance sheet
$ million
FY2018
FY2017
FY2016
On the year
Last 8 years
Shareholders' equity
479
335
518
+42.9%
Other liabilities
61.1
49.2
42.7
+24.2%
Total liabilities and equity
540
385
561
+40.5%
Fixed assets
3.3
2.7
3.1
+24.3%
Intangible assets
4.1
5.5
7.0
-26.7%
Investments
339
272
365
+24.6%
Cash and equivalents
135
69.4
164
+94.1%
Receivables
26.1
17.3
5.9
+50.4%
Inventory
4.1
5.2
4.2
-22.4%
Other assets
29.2
12.4
11.9
+135.6%
Total assets
540
385
561
+40.5%
10-K for the year ended 31 December 2018, filed 27 February 2019: the filing.